Search clinical trials for: mFOLFOXIRI + Cadonilimab

Total 169 results

Sun Yat-sen University

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer (OPTICAL-2)

Colorectal Cancer

China
The First Hospital of Jilin University

Not yet recruiting

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Lung Cancer
Peking University Cancer Hospital & Institute

Not yet recruiting

Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
Zhongnan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
West China Second University Hospital
The Affiliated Hospital Of Southwest Medical University; Afﬁliated Hospital...

Recruiting

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Cervical Cancer

China
Huazhong University of Science and Technology

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab

Recurrent Glioblastoma
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Azienda Ospedaliero, Universitaria Pisana

Completed

FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer (FLAP)

Pancreatic Carcinoma Stage III

Italy
Shengjing Hospital

Not yet recruiting

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Soft Tissue Sarcoma

China
Gang Chen (101199)

Not yet recruiting

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer
Fujian Cancer Hospital

Not yet recruiting

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Cervical Cancer
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Triple-negative Breast Cancer | Cadonilimab

China
Chongqing University Cancer Hospital
Akeso Pharmaceuticals, Inc.

Recruiting

Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Sun Yat-sen University

Active, not recruiting

A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
The First People's Hospital of Changzhou

Not yet recruiting

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital of Nanchang University
Fujian Cancer Hospital; Hunan Cancer Hospital

Not yet recruiting

Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases (CBC)

Non Small Cell Lung Cancer | Brain Metastases
Wuhan Union Hospital, China

Not yet recruiting

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Metastatic Colorectal Cancer

China
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC

Locally Advanced Rectal Cancer

China
Tianjin Medical University Second Hospital

Recruiting

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Bladder Cancer

China
Eastern Hepatobiliary Surgery Hospital

Active, not recruiting

Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

dMMR Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
Shen Feng

Active, not recruiting

Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Intrahepatic Cholangiocarcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Gastric Cancer

China
Fei Gao

Not yet recruiting

TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

Hepatocellular Carcinoma

China
AIPING ZHOU

Completed

Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Not yet recruiting

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Hepatocellular Carcinoma Non-resectable | Immune Checkpoint Inhibitors | Portal Vein Tumor Thrombus

China
Catharina Ziekenhuis Eindhoven

Not yet recruiting

Induction Chemotherapy for Locally Advanced Rectal Cancer (MEND-IT)

Rectal Cancer

Netherlands
Kasr El Aini Hospital

Completed

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

Egypt

3

Subscribe